Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs

Bruno Martoglio1,* and Todd E. Golde2,*

1Institute of Biochemistry, Swiss Federal Institute of Technology (ETH), ETH-Hoenggerberg, 8093 Zurich, Switzerland and 2Department of Neuroscience, Mayo Graduate School, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA

Received June 30, 2003; Accepted August 14, 2003

Recent studies demonstrate that presenilins (PSs) and signal peptide peptidase (SPP) are members of a novel protease family of integral membrane proteins that may utilize a catalytic mechanism similar to classic aspartic proteases such as pepsin, renin and cathepsin D. The defining features of the PSs and SPP are their ability to cleave substrate polypeptides within a transmembrane region, the presence of two active site aspartate residues in adjacent membrane-spanning regions and a conserved PAL motif near their COOH-terminus. PSs appear to be the catalytic subunit of multiprotein complexes that possess γ-secretase activity. Because this activity generates the amyloid β peptide (Aβ) deposited in the brain of patients with Alzheimer’s disease (AD), PSs are considered therapeutic targets in AD. In contrast to PSs that are not active unless part of a larger complex, SPP does not appear to require protein co-factors. Because of its requirement for hepatitis C virus maturation and a possible immune modulatory role, SPP is also considered a potential therapeutic target. Four additional PS/SPP homologs have been identified in humans; yet, their functions have not been elucidated. Herein, we will review the recent advances in our understanding of the PS/SPP family of proteases as well as discuss aspects of intramembrane cleavage that are not well understood.

INTRODUCTION

In order to more accurately reflect their catalytic activities, proteases have been referred to as peptide peptidohydrolases. This terminology reflects the catalytic mechanism in which a water molecule plays an essential role in cleaving a peptide bond. Until recently, all characterized ‘classic’ proteases had been shown to have an active site domain located in the aqueous environment of the cytoplasmic, lumenal or extracellular space. Thus, cleavage of peptide bonds buried within the hydrophobic interior of a cellular membrane was postulated to require either breakdown of the membrane or transport of substrate out of the lipid bilayer to an aqueous environment. The recent identification of several families of membrane proteases that seem capable of cleaving peptide bonds present within the lipid bilayer has dramatically changed the concept of how transmembrane regions of proteins may be cleaved (1,2).

Three families of proteases that carry out ‘intramembrane proteolysis’ are recognized (1,2). Though exact catalytic mechanisms remain elusive, there is evidence that the active site of these proteases could lie within the plane of the lipid bilayer, and that proteases within each family may utilize conserved catalytic mechanisms analogous to those found in classic proteases. The first family, whose prototypic member is the human site-two protease (S2P) that cleaves and activates sterol regulatory element binding proteins (SREBPs), appears to be a group of metalloproteases (3). The second family, the rhomboids, whose prototypic member Drosophila Rhomboid-1 cleaves and liberates several EGF ligands, appears to be a group of serine proteases (4). A third family, whose prototypic members are the presenilins (PSs) involved in cleavage of the amyloid β protein precursor (APP) and Notch, appears to be a group of aspartic proteases (5,6). Collectively these proteases have been referred to as intramembrane-cleaving proteases (I-CLiPs). For several reasons a great deal of attention has focused on the aspartic I-CLiP family. First, the prototypic members of this family, the human PSs, are therapeutic targets in Alzheimer’s disease (AD). Second, a new member of this family, signal peptide peptidase (SPP), was recently identified and shown unequivocally to possess proteolytic activity and have...
biological functions that may also make it a therapeutic target. Herein, we will discuss these recent advances with respect to the presenilin/signal peptide peptidase family of I-CLiPs.

**PRESENILINS**

PSs are integral membrane proteins with 6–8 predicted transmembrane regions. They were first identified through genetic linkage analysis in families with early onset autosomal dominant forms of AD (7,8). PSs are synthesized as ~50 kDa proteins, but are rapidly endoproteolyzed into NH2- (ps2) and COOH- (~20 kDa) terminal fragments, which remain associated along with other proteins in a high molecular weight complex (9,10). To date, ~100 AD-linked mutations have been found in presenilin 1 (PS1) and several more in presenilin 2 (PS2) (11). Almost concurrent with the identification of mutations in PSs as genetic causes of AD, there was some evidence linking PSs to the proteolytic activity referred to as \( \gamma \)-secretase (12). This activity is involved in the production of the amyloid \( \beta \) peptide (A\( \beta \)) from its precursor, APP. Following cleavage of APP by \( \beta \)-secretase, \( \gamma \)-secretase cleaves the membrane bound COOH-terminal APP fragment within its transmembrane region generating both the ~4-kDa A\( \beta \) peptide and a cognate COOH-terminal cleavage product. The cut in the membrane is heterogeneous with multiple A\( \beta \) species produced ranging in length from 32–42 amino acids (13). The most prevalent form of A\( \beta \) is one of 40 amino acid residues (A\( \beta \)40); under typical circumstances A\( \beta \)40 represents >50% of the A\( \beta \) secreted from a cell. However, an A\( \beta \) species of 42 amino acids (A\( \beta \)42) appears to play a causal role in AD pathogenesis. To date, all AD-linked mutations in PS1 and PS2 have been shown to increase the relative production of A\( \beta \)42 even in asymptomatic carriers, and expression of a mutant PS gene in transgenic mice overexpressing human APP, accelerated accumulation and aggregation of A\( \beta \) in the brain (12,14).

Despite the evidence that mutations in PSs altered the \( \gamma \)-secretase activity that generated A\( \beta \), no one readily endorsed the idea that PSs were \( \gamma \)-secretases. PSs did not bear homology to classic proteases; thus, it was proposed that PSs influenced \( \gamma \)-secretase activity indirectly. Over the past few years, genetic and biochemical evidence has emerged demonstrating that PSs are in fact \( \gamma \)-secretases. Knockout studies of PS1 and PS2 demonstrated an essential role of these proteins in \( \gamma \)-secretase cleavage. PS1 knockout decreased \( \gamma \)-secretase activity by ~80%, a PS2 knockout had little or no effect, and a combined PS1 and PS2 knockout abolished \( \gamma \)-secretase activity (15–18). Biochemical studies showed that PS1 co-fractionates with \( \gamma \)-secretase activity in a high molecular weight complex and this in vitro activity could be recovered in the pellet after immunoprecipitation with antibodies to PS1 (19). Significantly, mutation of conserved aspartate residues (D257 and D385 in PS1, and D263 and D366 in PS2) present in two adjacent transmembrane regions produced dominant negative forms of PS that inhibited \( \gamma \)-secretase activity in cells (5). These studies together with inhibitor studies suggested that PSs might be aspartic type proteases (20). Finally, inhibitors of \( \gamma \)-secretase activity have been shown to directly target both PS1 and PS2 (21–24). Moreover, given that two groups had specifically designed their inhibitors to be transition state analogs of aspartic proteases (21,22), it certainly appears that despite the lack of demonstrable homology to known aspartic proteases, PS may be just that.

Recent insight into the other components of the high molecular weight complex that contains \( \gamma \)-secretase activity and PSs, now offers a more complete picture of \( \gamma \)-secretase. Three additional proteins are required for \( \gamma \)-secretase activity in cells. Nicastrin (Net, APH-2) is a ~130 kDa type I membrane protein that was originally purified from the complex (25). Two additional proteins, APH-1, another integral membrane protein of ~30 kDa with multiple transmembrane regions, and PEN-2, a small hairpin like protein of ~12 kDa, were initially isolated from genetic screens in *Caenorhabditis elegans* (26). Together with a PS, the three components appear to comprise a minimal functional \( \gamma \)-secretase complex (27–29). Although the precise function of each subunit is not yet definitively established, it appears that PSs are the catalytic component, and that Net, APH-1 and PEN-2 play various roles in the stabilization and maturation of the complex. It is also possible that these ‘accessory’ proteins are involved in substrate presentation.

The biological activities of \( \gamma \)-secretase and PSs have been extensively reviewed (2,30). Although some activities of PSs are distinct from their protease activity (e.g. stabilization of \( \beta \)-catenin), many are not. \( \gamma \)-Secretase activity regulates Notch and APP signaling by promoting the release of the cytoplasmic tail from a membrane bound fragment of each precursor. It is not clear whether the release of small peptides, such as A\( \beta \), into the exoplasmic space has any demonstrable physiologic function. It is also not clear whether \( \gamma \)-secretase cleavage of substrates other than Notch and APP has some physiologic functions. It is possible that \( \gamma \)-secretase cleavage of certain substrates may simply be a mechanism to breakdown these proteins. A current list of \( \gamma \)-secretase substrates, cleavage products and putative functions are listed in Table 1.

**SIGNAL PEPTIDE PEPTIDASE**

The second, more recently identified member of the aspartic I-CLiP family is the SPP of higher eukaryotes (31). Typical for an aspartic I-CLiP, SPP is a predicted multispanning membrane protein containing two putative active site aspartates that are located in the centre of adjacent transmembrane regions. The latter feature is consistent with the observed cleavage of substrate peptides in the centre of their membrane-spanning portion. In addition, SPP contains two endoglycosidase H-sensitive N-glycans and an ER retrieval signal, KKxx, ascribing SPP a function in the endoplasmic reticulum (ER) (31).

The role of SPP in cell function is poorly understood. The SPP substrates identified to date, represent a variety of signal peptides and a viral protein (Table 2) (31–34). They do not unequivocally demonstrate to a role of SPP either in the degradation of signal peptides that may otherwise accumulate in the ER membrane, or in the activation of signaling or regulatory molecules, or both. Potential orthologs of SPP are found in the genomes of animals and plants but not fungi and bacteria (31,35). Therefore, the prime role of SPP may not necessarily be the clearance of membranes from signal peptides, which are produced in all organisms, and a more basic mechanism may exist to fulfill that function. We may thus
speculate that SPP, in analogy to other I-CLiPs, may promote the liberation of bioactive peptides or proteins from the ER membrane. The generation of HLA-E epitopes in humans represents the first example of such an SPP-dependent production of a bioactive peptide, which in this case functions as a reporter. HLA-E epitopes that play a key role in immune surveillance, are produced from the signal sequences of the antigen presenting MHC class I molecules in a process that depends on SPP (36). The epitopes are eventually presented at the cell surface of most of our cells, where they are recognized by the natural killer (NK) cells of the immune system. Presentation of these signal peptide-derived epitopes is an indirect indication that the probed cell is healthy and had properly synthesized MHC class I molecules. If such epitope presentation is defective or otherwise disturbed, e.g. due to a virus infection or transformation to a tumor cell, these impaired cells are thought to be recognized and eliminated by the NK cells (37).

The substrate spectrum of SPP may not be restricted to classic signal peptides, which typically are short, NH2-terminal extensions of a precursor protein. The finding that SPP is exploited by the hepatitis C virus (HCV) for the processing of the viral core protein, implies that the protease may also catalyse intramembrane cleavage of membrane anchored proteins, similar to other I-CLiPs (34). During biosynthesis of viral proteins in HCV infected cells, the immature HCV core protein is transiently anchored in the ER membrane via a COOH-terminal, signal peptide-like sequence. Intramembrane proteolysis by SPP promotes the final processing of core protein and its release from the ER membrane into the cytosol. Likewise, we may speculate that proteins anchored in the ER membrane by a signal peptide-like sequence, may be liberated from the ER membrane and activated upon cleavage by SPP.

**PRESENILIN AND SPP: SIMILARITIES AND DIFFERENCES**

Despite limited areas of direct sequence homology, PSs and SPP are membrane proteins whose sequences can be aligned almost throughout their entire lengths (31,35). PSs and SPP share identical active site motifs, YD and LGLGD (Table 3). In addition, they contain a third conserved region, PAL, which seems characteristic for the entire aspartic I-CLiP family. Moreover, the YD and LGLGD motifs, which contain the catalytic aspartate residues, are unusual in that they are present within predicted adjacent and opposing transmembrane regions. The similarities between PSs and SPP, particularly the identity of the active site motifs, point to a common catalytic mechanism. Indeed, a series of protease inhibitors including aspartic protease transition state analogues, targeted to the active site of SPP and PSs, inhibited both activities (38). Because both enzymes are potential targets for therapeutic intervention—PSs for the treatment of AD and SPP for the anti HCV therapy—it will be a challenging task for the future to define compounds and conditions for the selective inhibition of either protease.

Another common feature, and one that is typical of many I-CLiPs, is that both PS and SPP activity appear to require prior cleavage of the substrate to remove its ectodomain. SPP substrates are first cleaved by signal peptidase (33), whereas PS/γ-secretase and SPP may be determined as substrates that have both their NH2-terminal extensions of a precursor protein. The finding that SPP is exploited by the hepatitis C virus (HCV) for the processing of the viral core protein, implies that the protease may also catalyse intramembrane cleavage of membrane anchored proteins, similar to other I-CLiPs (34). During biosynthesis of viral proteins in HCV infected cells, the immature HCV core protein is transiently anchored in the ER membrane via a COOH-terminal, signal peptide-like sequence. Intramembrane proteolysis by SPP promotes the final processing of core protein and its release from the ER membrane into the cytosol. Likewise, we may speculate that proteins anchored in the ER membrane by a signal peptide-like sequence, may be liberated from the ER membrane and activated upon cleavage by SPP.

**Table 1. PS/γ-secretase substrates**

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Relevant fragments</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>Aβ and cytoplasmic domain (AID, AICD)</td>
<td>AD: Nuclear signaling in complex with TIF; regulation of ER calcium stores. Aβ: physiologic role unknown, pathologic role in AD</td>
</tr>
<tr>
<td>APLP1</td>
<td>Cytoplasmic domain</td>
<td>Nuclear signaling?</td>
</tr>
<tr>
<td>APLP2</td>
<td>Cytoplasmic domain</td>
<td>Nuclear signaling?</td>
</tr>
<tr>
<td>Notch 1-4</td>
<td>Cytoplasmic domain (NICD)</td>
<td>Nuclear signaling in complex with transcription factor.</td>
</tr>
<tr>
<td>Erb-B4</td>
<td>Cytoplasmic domain (S80)</td>
<td>Signaling by translocation of kinase domain to nucleus.</td>
</tr>
<tr>
<td>E-Cadherin</td>
<td>Cytoplasmic domain</td>
<td>Regulation of adherens junction?</td>
</tr>
<tr>
<td>LRP</td>
<td>Cytoplasmic domain</td>
<td>Unknown</td>
</tr>
<tr>
<td>Delta-1 and Jagged</td>
<td>Cytoplasmic domain</td>
<td>Antagonist role in Notch signaling?</td>
</tr>
<tr>
<td>Nectin-1x</td>
<td>Cytoplasmic domain</td>
<td>Unknown</td>
</tr>
<tr>
<td>CD44</td>
<td>Cytoplasmic domain</td>
<td>Signaling?</td>
</tr>
</tbody>
</table>

**Table 2. SPP substrates**

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Relevant fragments</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signal peptides of human MHC class I molecules</td>
<td>HLA-E epitope</td>
<td>Immune surveillance</td>
</tr>
<tr>
<td>Signal peptide of prolactin</td>
<td>Cytoplasmic portion of signal peptide</td>
<td>Calmodulin signaling? (enhancer of prolactin secretion?)</td>
</tr>
<tr>
<td>Hepatitis C virus polyprotein</td>
<td>HCV core protein</td>
<td>Subunit of virus capsid</td>
</tr>
</tbody>
</table>

Despite limited areas of direct sequence homology, PSs and SPP are membrane proteins whose sequences can be aligned throughout their entire lengths (31,35). PSs and SPP share identical active site motifs, YD and LGLGD (Table 3). In addition, they contain a third conserved region, PAL, which seems characteristic for the entire aspartic I-CLiP family. Moreover, the YD and LGLGD motifs, which contain the catalytic aspartate residues, are unusual in that they are present within predicted adjacent and opposing transmembrane regions. The similarities between PSs and SPP, particularly the identity of the active site motifs, point to a common catalytic mechanism. Indeed, a series of protease inhibitors including aspartic protease transition state analogues, targeted to the active site of SPP and PSs, inhibited both activities (38). Because both enzymes are potential targets for therapeutic intervention—PSs for the treatment of AD and SPP for the anti HCV therapy—it will be a challenging task for the future to define compounds and conditions for the selective inhibition of either protease.
with these additional proteins, forms an active γ-secretase complex. Such activation and complex formation may provide means of control of the protease’s intramembrane-cleaving activity, and regulate substrate delivery and/or trafficking to the intracellular site of action. In the case of SPP, there is no indication for endoproteolysis or any another activation step. Nevertheless, its activity is almost certainly regulated in some fashion; SPP does not appear to randomly attack membrane proteins in the ER. Rather than the protease activity, properties of the substrates may account for controlled proteolysis by SPP (33).

**OTHER HOMOLOGS**

Shortly after the identification of human PSs, homologs were recognized in plants, invertebrates and vertebrates. Some of the close homologs such as those found in *C. elegans* and *Drosophila*, have been extensively studied and shown to function as aspartic I-CLiPs in high molecular weight complexes like the human PSs (reviewed in 2). More recently, in addition to SPP, a number of other potential aspartic I-CLiPs with less obvious homology to PSs have been recognized by database searching (Table 3) (31,35,43). These proteins have no identified function and have been referred to by various names. Herein, they will be referred to as presenilin homologs/signal peptide peptidase-like proteases (PSH/SPPL), although with future functional assignment we propose that they would be renamed to more accurately reflect their function. In humans, four PSH/SPPLs with unknown functions have been recognized. PSH/SPPLs are predicted to be integral membrane proteins with multiple membrane spanning regions, and to contain both the conserved transmembrane aspartates in the motifs YD and LGhGD, and the PAL motif near the COOH-terminus. In addition, several members of the family contain a protease-associated domain near their NH2-terminus. When found in some classic protease, this domain is involved in substrate binding (44).

**MODELS OF CLEAVAGE**

Although much has been learned about intramembrane cleavage, the exact manner in which these reactions occur remains a mystery. The conservation of putative active site motifs between I-CLiPs and classic proteases indicates that the catalytic mechanism of I-CLiPs most likely involves hydrolysis. If this is the case, then water must somehow gain entry into the active site of these proteases and the labile bonds within the substrate’s transmembrane region must at some point be exposed to an activated water molecule. In Figure 1,
CONCLUSIONS

The aspartic I-CLiPs represent a newly recognized and biomedically important family of proteases. Intense study of PSs and γ-secretase has led to the development of potent inhibitors of γ-secretase activity several of which have entered phase I trials in humans. Distinct γ-secretase inhibitors have overlapping activity against SPP (38), it is highly expected that many of those compounds may also target the other PSH/SPPls. Thus, the specificity of γ-secretase inhibitors must be questioned. Because of the potential clinical significance of γ-secretase inhibitors, there is urgent need to increase our understanding of these proteins. Even with the experience gained by studying PSs and SPP, this will remain a difficult task. To date, there is no easily identifiable strategy that is assured of identifying function or substrate for these novel aspartic I-CLiPs. Nevertheless, because inhibitor specificity may prove instrumental, if inhibitors of aspartic I-CLiPs prove to be of therapeutic utility, this assignment of function and development of activity assays for each is extremely important.

ACKNOWLEDGEMENTS

This work was supported by grants from the NIH/NIA (NS39072 to T.E.G.), and the Center of Neuroscience Zurich (ZNZ), the National Competence Center for Research (NCCR) ‘Neuronal Plasticity and Repair’, and the Swiss National Science Foundation (to B.M.).

REFERENCES

27. Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H. and Haass, C.
28. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M.,
22. Li, Y.M., Xu, M., Lai, M.T., Huang, Q., Castro, J.L., DiMuzio-Mower, J.,
25. Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A.,
31. Weihofen, A., Bins, K., Lemberg, M.K., Ashman, K. and Martoglio, B.
32. Weihofen, A., Lemberg, M.K., Ploeh, H.L., Bogos, M. and Martoglio, B.
35. Ponting, C.P., Hutton, M., Nyborg, A., Baker, M., Jansen, K. and
37. Carbone, V., Reinhard, F.B., Weidemann, A., Evin, G.
38. Weihofen, A., Lemberg, M.K., Culvenor, J.G., Holsinger, R.M., Sernee, M.F.,
40. Doan, A., Thinakaran, G., Borchelt, D.R., Slunt, H.H., Ratovitsky, T.,
41. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R.,
42. Doan, A., Thinakaran, G., Borchelt, D.R., Slunt, H.H., Ratovitsky, T.,
45. Masters, C.L. (2001) Aspartyl protease inhibitor pepstatin binds to the
46. Ashman, K. and Martoglio, B.
47. Song, Y.Q., Rogaeva, E., Chen, F., Kawarai, T.
48. Donegan, M., Kojro, E., Podlisny, M., Selkoe, D.J., Seeger, M., Gandy, S.E.,
49. Selkoe, D.J., Seeger, M., Gandy, S.E., Price, D.L.
50. Harrison, T., Lellis, C., Nadin, A., Neduvelil, J.G.
51. Doan, A., Thinakaran, G., Borchelt, D.R., Slunt, H.H., Ratovitsky, T.,
52. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M.,
53. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M.,
54. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M.,
55. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M.,